Held by 3 specialist biotech funds
High Convergence# Signal Note: Rock Springs Capital Initiates NAMSW Position Rock Springs' $19.5M entry into NewAmsterdam reflects conviction in obicetrapib, the company's CETP inhibitor in late-stage development for cardiovascular risk reduction.
AI analyst context — unlock full analysis
**Signal Note: RA Capital Initiates $342.7M Position in NewAmsterdam Pharma** RA Capital's $343M entry into NAMSW signals conviction in obicetrapib, NewAmsterdam's CETP inhibitor for cardiovascular risk reduction in statin-intolerant patients. The position timing likely reflects confidence ahead of Phase 3 readout expectations and potential regulatory pathway clarity, as CETP inhibitors have faced historical skepticism but recent apoB-lowering data may support differentiation. This represents meaningful validation from a top-tier biotech investor with strong track record in precision/cardiometabolic assets.
+ 1more — see how much conviction went in
See the Full Story